Tokyo Tape
Sign in
← Nihon Chouzai

Quarterly report · Q1

3341.TEDINET S100RN0R
Period2023-04-01 → 2023-06-30
Filed2023-08-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥81.8bn2023-04-01 → 2023-06-30Cons.Net sales
Revenue¥313.3bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥74.7bn2022-04-01 → 2022-06-30Cons.Net sales
Operating income¥1.6bn2023-04-01 → 2023-06-30Cons.Operating income
Operating income¥892m2022-04-01 → 2022-06-30Cons.Operating income
Ordinary income¥1.6bn2023-04-01 → 2023-06-30Cons.Ordinary income
Ordinary income¥7.7bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥913m2022-04-01 → 2022-06-30Cons.Ordinary income
Profit before tax¥1.6bn2023-04-01 → 2023-06-30Cons.Income before income taxes
Profit before tax¥925m2022-04-01 → 2022-06-30Cons.Income before income taxes
Net income (owners)¥659m2023-04-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.5bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥391m2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income¥659m2023-04-01 → 2023-06-30Cons.Profit loss
Net income¥391m2022-04-01 → 2022-06-30Cons.Profit loss
Total assets¥199.2bnat 2023-06-30Cons.Assets
Total assets¥185.3bnat 2023-03-31Cons.Assets
Total assets¥195.3bnat 2022-06-30Cons.Total assets (5-year summary)
Total liabilities¥142.4bnat 2023-06-30Cons.Liabilities
Total liabilities¥128.8bnat 2023-03-31Cons.Liabilities
Net assets / equity¥56.8bnat 2023-06-30Cons.Net assets
Net assets / equity¥56.5bnat 2023-03-31Cons.Net assets
Net assets / equity¥52.9bnat 2022-06-30Cons.Net assets (5-year summary)
Cash and deposits¥31.2bnat 2023-06-30Cons.Cash and deposits
Cash and deposits¥23.8bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥22.062023-04-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥148.922022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥13.052022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio28.5%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio30.5%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio27.1%at 2022-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30−¥3.6bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30−¥3.6bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30−¥1.9bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥72.3bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥72.3bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥2.9bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥2.6bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥2.6bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥5m
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥484m
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥10.5bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥7.0bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥3.6bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥126m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-06-30¥85.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-06-30¥81.8bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-06-30¥3.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-06-30¥3.5bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥3.8bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥3.8bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥1.8bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥66.4bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥66.4bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥2.1bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥2.1bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥2.1bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥3m
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥355m
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥10.0bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥6.3bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥3.8bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥270m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥78.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥74.7bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥3.8bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥2.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 351
ItemContextValueUnit
Net salesPrior1YTDDuration74709000000JPY
Net salesCurrentYTDDuration81848000000JPY
Cost of salesPrior1YTDDuration61928000000JPY
Cost of salesCurrentYTDDuration68067000000JPY
Gross profitPrior1YTDDuration12780000000JPY
Gross profitCurrentYTDDuration13781000000JPY
Selling general and administrative expensesPrior1YTDDuration11888000000JPY
Selling general and administrative expensesCurrentYTDDuration12185000000JPY
Operating incomePrior1YTDDuration892000000JPY
Operating incomeCurrentYTDDuration1596000000JPY
Commission fee noiPrior1YTDDuration9000000JPY
Commission fee noiCurrentYTDDuration11000000JPY
Rent income noiPrior1YTDDuration142000000JPY
Rent income noiCurrentYTDDuration153000000JPY
Insurance income noiPrior1YTDDuration40000000JPY
Insurance income noiCurrentYTDDuration－JPY
Subsidy income noiPrior1YTDDuration17000000JPY
Subsidy income noiCurrentYTDDuration19000000JPY
Other noiPrior1YTDDuration62000000JPY
Other noiCurrentYTDDuration46000000JPY
Non operating incomePrior1YTDDuration271000000JPY
Non operating incomeCurrentYTDDuration231000000JPY
Interest expenses noePrior1YTDDuration64000000JPY
Interest expenses noeCurrentYTDDuration64000000JPY
Rent expense noePrior1YTDDuration107000000JPY
Rent expense noeCurrentYTDDuration99000000JPY
Other noePrior1YTDDuration78000000JPY
Other noeCurrentYTDDuration58000000JPY
Non operating expensesPrior1YTDDuration250000000JPY
Non operating expensesCurrentYTDDuration222000000JPY
Ordinary incomePrior1YTDDuration913000000JPY
Ordinary incomeCurrentYTDDuration1605000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration11000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration0JPY
Extraordinary incomePrior1YTDDuration11000000JPY
Extraordinary incomeCurrentYTDDuration0JPY
Loss on sales of noncurrent assets elPrior1YTDDuration0JPY
Loss on sales of noncurrent assets elCurrentYTDDuration－JPY
Extraordinary lossPrior1YTDDuration0JPY
Extraordinary lossCurrentYTDDuration－JPY
Income before income taxesPrior1YTDDuration925000000JPY
Income before income taxesCurrentYTDDuration1605000000JPY
Income taxes currentPrior1YTDDuration888000000JPY
Income taxes currentCurrentYTDDuration1305000000JPY
Income taxes deferredPrior1YTDDuration-354000000JPY
Income taxes deferredCurrentYTDDuration-359000000JPY
Income taxesPrior1YTDDuration534000000JPY
Income taxesCurrentYTDDuration945000000JPY
Profit lossPrior1YTDDuration391000000JPY
Profit lossCurrentYTDDuration659000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass